USD 710.0 million
Endobronchial Ultrasound Biopsy Market Size, Share, and Growth Analysis
Endobronchial Ultrasound Biopsy Market By Product (EBUS Scopes, EBUS Needles), By Procedure (EBUS-Transbronchial Needle Aspiration (EBUS-TBNA), EBUS-Guided Biopsy), By End use (Hospitals, Ambulatory Surgical Centers (ASCs)), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35G2331 |
Region:
Global |
Published Date: July, 2025
Pages:
180
|Tables:
94
|Figures:
76
Format -
Endobronchial Ultrasound Biopsy Market Insights
Global Endobronchial Ultrasound Biopsy Market size was valued at USD 710.0 million in 2023 and is poised to grow from USD 744.79 million in 2024 to USD 1092.04 million by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).
The endobronchial ultrasound biopsy (EBUS) market is growing steadily from an emerging market after an increased global focus on the early diagnosis of lung cancer and a global shift towards less invasive techniques. Technological upgrades to EBUS scopes, needles, and ultrasound processors are making EBUS procedures significantly more precise, driving demand from hospitals and specialist clinics. Meanwhile, the global population is aging and at the same time an increase in respiratory disease (COPD, tuberculosis) is driving the need for EBUS diagnosis; allowing a better diagnosis of lung disease for advanced economies and entering emerging economies with a strong diagnosis basis like Japan, China, and India.
However, the drive for market growth is somewhat limited by the price of the equipment and procedures which limits EBUS adaptation in cost effective environments. Moreover, reimbursement policies globally, especially in low- to middle-income countries remain inconsistent, impeding EBUS implementation in this segment. Notably, there remains great interest from hospitals and ambulatory care centers globally, particularly with the development of clinical pathways showing good clinical outcomes and funding support.
How Artificial Intelligence is Changing the Endobronchial Ultrasound Biopsy Market?
Artificial Intelligence (AI) continues to reshape the endobronchial ultrasound biopsy market by facilitating accurate image interpretation, better planning of procedures, and providing real-time diagnostic support to clinicians performing EBUS-guided biopsies. The AI algorithms in EBUS platforms are capable of analyzing ultrasound data for lymph node characteristics and optimizing needle placement for ultrasound-guided diagnostics while simultaneously increasing diagnostic accuracy and efficiency by reducing procedure time. Implementing AI capabilities is also assisting bronchoscopists with real-time decision making for TBNA, which is expected to improve patient outcomes and minimize the variation in clinician performance. Overall, these AI developments are streamlined procedural workflows and enabling early-stage lung cancer diagnostics in resource-limited environments and less-resourced conditions.
In April 2024, Olympus Corporation is launching the EVIS X1 endoscopic system, which is designed with AI-enabled machine learning algorithms to identify lesions as well as eliminate the need for additional knowledge acquisition and support the clinician with real-time diagnostic assistance during EBUS-guided biopsy of lesions in the lung. The incorporation of pattern recognition identifies difficult access situations for lung nodules, while providing a visible indicator of correct biopsy accompaniment. Several clinical trials in Japan and Germany demonstrated a clear improvement in diagnostic yield while minimizing complications in patients with early-stage lung cancer. This technological advancement is significant from both an integrated AI enabled endoscopy standpoint and as a potential shift towards larger data-providing precision-guided minimally invasive diagnostics in pulmonology.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Biopsy Needles
Fastest Growth
Spray Catheters
Growth Rate
4.9% CAGR
Global Endobronchial Ultrasound Biopsy Market ($ Bn)
Country Share by North America (%)
To get more reports on the above market click here to Buy The Report
Endobronchial Ultrasound Biopsy Market Segments Analysis
Global Endobronchial Ultrasound Biopsy Market is segmented by Product, Procedure, End use and region. Based on Product, the market is segmented into EBUS Scopes, EBUS Needles, Ultrasound Processors & Imaging Systems and Accessories. Based on Procedure, the market is segmented into EBUS-Transbronchial Needle Aspiration (EBUS-TBNA) and EBUS-Guided Biopsy. Based on End use, the market is segmented into Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Which Product Category in the Endobronchial Ultrasound Biopsy Market Contributes the Most to Revenue Generation?
Biopsy needles are the leading product type in the endobronchial ultrasound biopsy market because of their importance in TBNA, the most important operation performed by EBUS. Biopsy needles provide access to mediastinal and hilar lymph nodes, enabling clinicians to obtain tissue for histopathological and molecular testing for lung cancer and infection. Many new needle innovations, including echogenic tips, the ability to flex for angulated bronchoscopes (and therefore diagnostic and staging procedures), and ability to obtain better core samples further added to their strength as a component of EBUS-guided sampling. With the increased global incidence of lung cancer and the clinical need for less invasive diagnostic workflows, biopsy needles are at the forefront of EBUS-guided sampling, and as a result, continue to dominate the biopsy needle market.
Spray catheters are developing as the fastest growing product sub-segment, due to an increasing presence in diagnostic procedures that require airway preparation or direct drug delivery. As their role in pre-biopsy mucosal management, especially pre-biopsy mucosal management before diagnostic procedures related to infection and in airway visualization expands, they are becoming increasingly relevant. Innovations such as compact designs, compatibility with sophisticated bronchoscopes, and direct delivery bolster the growth of this sub-segment.
Which Clinical Application Segment Contributes Most to the growth of the Endobroncial Ultrasound Biopsy Market?
Cancer Diagnosis is dominating application segment in the endobronchial ultrasound biopsy market, as it serves a critical need for detection, staging and monitoring of lung cancers. EBUS-TBNA offers a less invasive and more accurate way to sample mediastinal lymph nodes compared to mediastinoscopy. Clinical guidelines recommend the use of EBUS for staging of non-small cell lung cancer (NSCLC). The growing incidence of lung cancer, aging populations, and increased use of early screening programs—especially in high-risk patient populations are drives of the demand in this segment. The segment also benefits from procedural reimbursement in developed markets, which helped make it the largest segment of the EBUS market.
Infection Diagnosis is the fastest-growing application segment, largely due to a global rise in tuberculosis, fungal infections and other respiratory diseases. In situations where imaging cannot provide a definitive diagnosis, EBUS provides a safe and effective method to obtain diagnostic samples. The growing focus on diagnostic accuracy in immunocompromised patients and suspected drug-resistance TB patients has also contributed to growth in procedures in this area. In addition, the increasing number of hospitals and diagnostic centers equipped with EBUS systems suggests that this application will continue to expand in the market.
Global Endobronchial Ultrasound Biopsy Market By Product Type (%)
To get detailed analysis on other segments, Request For Free Sample Report
Endobronchial Ultrasound Biopsy Market Regional Insights
What Key Factors are Supporting North America's Leading Position in the Endobronchial Ultrasound Biopsy Market?
North America is the number one region for the global endobronchial ultrasound biopsy market due to many reasons, such as its highly developed healthcare infrastructure across the region, the quick uptake of advanced diagnostic technologies, and the rising prevalence of lung cancer. The favourable reimbursement policies and strong clinical research support for effective implementation of the procedure into practice has contributed to its successful introduction into routine practice. The collaboration of medical device companies with research hospitals has facilitated the design, implementation, and acceptance of AI-guided bronchoscopic systems and other advanced diagnostic systems.
United States Endobronchial Ultrasound Biopsy Market
The USA contributes the most and continues to also be the first in this region, which we anticipate will further grow in 2024, as they become familiarized with these procedures and the very high disease burden they have. For example, Boston Scientific entered the EBUS space earlier in 2024 with the launch of a new high-resolution ultrasound processor with AI-guided lymph node classification. This offer included a strategic effort to promote their EBUS product. This was supported by a simultaneous Launch across 94 U.S. hospitals identified by the National Cancer Institute for the advanced clinical use of the EBUS product. This indicates a dedicated effort towards technology adoption and standardization of lung cancer diagnostic practice.
Canada Endobronchial Ultrasound Biopsy Market
Canada’s emerging EBUS market is driven by its centralized healthcare system and growing momentum around early cancer detection through non-invasive techniques. In 2025, Health Canada authorized a public-private plan to increase regional hospital access to EBUS systems throughout British Columbia and Ontario. The expansion is funded through the Canadian Partnership Against Cancer, with plans to pilot the EBUS project through their early diagnosis program. The intention of the initiative is to provide EBUS-TBNA services in underserved locations and provide timely cancer diagnoses. The funds are allowing for more equitable access to EBUS-TBNA services in remote, underserved regions as well as mitigating delays in the diagnostic process.
What Conditions Are Fuelling Asia Pacific’s Rapid Growth in the Endobronchial Ultrasound Biopsy Market?
The Asia Pacific region has become the fastest-growing area of the endobronchial ultrasound biopsy market, due to the growing awareness of lung cancer; growing healthcare cost, and demand for non-invasive diagnostics. The effects of an aging population and the rising levels of respiratory diseases are putting an increasing amount of pressure on health systems to utilize accurate and cost-effective diagnostic procedures. An influx of local and international equipment manufacturers is expanding their presence in the market along with the availability of regional equipment, and the growing number of clinical training programs. Government awareness programs supporting early-stage oncology diagnostics and initiatives to support innovation and public-private R&D programs will support the future development and growth of the Asia-Pacific region for years to come.
Japan Endobronchial Ultrasound Biopsy Market
Japan has adapted early to utilize endobronchial ultrasound biopsy technology and embraced the widespread use of minimally invasive procedures, and the void created by their large aging population. In 2024, Olympus started a national training program with the goal of assisting pulmonary medicine physicians accelerate their competencies with robotic-assisted EBUS biopsy procedures. The training program is part of a broader conceptual strategy to integrate AI-assisted imaging embedded with EBUS systems in community hospitals and academic hospitals in Japan, to improve the efficiencies of diagnosis.
South Korea Endobronchial Ultrasound Biopsy Market
South Korea has seized a significant opportunity for growth in endobronchial ultrasound biopsy implementation of its national cancer screening programs. In 2025, Seoul National University Hospital partnered with the domestic startup Lunit to provide image guidance using AI-based algorithms for lung cancer staging through EBUS bronchoscopy. The project produced targeted lymph node accuracy, 15% faster biopsy procedures for staged lung cancer patients and early validation of AI for future EBUS applications. South Korea is uniquely positioned to contribute significantly to EBUS technology development, and by leveraging existing digital infrastructure, financed innovation by the government and willingness among local industry.
How is Europe Advancing the Clinical and Technological Uptake of Endobronchial Ultrasound Biopsy Market?
The Endobronchial Ultrasound Biopsy Market in Europe is characterized by well-developed medical infrastructures, robust hospital-based clinical research networks, and earlier adoption of imaging related to clinical diagnostics. The regulatory environment to support high-performance diagnostic tools, as well as preferences for day-care procedures in pulmonary conditions are drivers. Furthermore, growing European Union support for lung cancer screening and early diagnosis are encouraging better conditions for EBUS systems in both public and private healthcare systems.
Germany Endobronchial Ultrasound Biopsy Market
Germany has sustained its position as the front runner in the region for EBUS usage due to experienced hospitals, and a public health context with pulmonology playing the role as the leader of digital health innovation. In 2024, the German Cancer Research Centre participated in a co-development with ERBE Elektromedizin GmbH on a new advanced EBUS-TBNA with high-fidelity, real-time tissue density mapping capabilities. Clinical trials have been organized at key teaching hospitals, and it represents a major advancement to AI-enabled biopsy accuracy.
United Kingdom Endobronchial Ultrasound Biopsy Market
The United Kingdom is expediting its EBUS biopsy adoption through the National Health Services (NHS) driven lung health initiatives. In 2025, NHS England opened its Targeted Lung Health Checks (TLHC) initiative to allow for real-time access to EBUS services inside mobile diagnostic units. These units are intended to deploy into underserved areas and complement the UK Health System's broader overall approach to early-stage cancer interventions. Investment in clinician training and mobile diagnostic infrastructure are both fast-tracking access to market and throughput of procedures.
France Endobronchial Ultrasound Biopsy Market
France too is establishing its EBUS market through national investments in minimally invasive diagnostics and the standardization of lung cancer care. In 2025, the French National Cancer Institute (Institut National Du Cancer or INCa) initiated a robot assisted EBUS biopsy navigation project in partnership with public hospitals in Lyon and Marseille, to decrease diagnostic variability across the regions. This project is part of France's overarching Plan Cancer 2021-2030 with the principle of early detection and equitable access to innovative and advanced diagnostic technologies. This plan is anticipated to improve regional coverage of EBUS and provide critical government assistance for clinical integration to market expansion.
Global Endobronchial Ultrasound Biopsy Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Endobronchial Ultrasound Biopsy Market Dynamics
Endobronchial Ultrasound Biopsy Market Drivers
Rising Prevalence of Lung Cancer and Respiratory Disorders
- Rising global incidence of lung cancer and other pulmonary diseases are currently the primary motivators of the Endobronchial Ultrasound (EBUS) Biopsy Market. EBUS procedures are a minimally invasive way to access mediastinal and hilar lymph nodes to stage and diagnose lung malignancies. In an increasingly health-conscious world, countries around the world have been developing an awareness of the importance of at minimum, late-stage detection and there is an increasing use of lung cancer screening programs internationally across both advanced and emerging healthcare economies developing. As healthcare systems evolve, there is a push for alternatives to surgical pathology and flexible bronchoscopy, which has raised the profile of EBUS-TBNA, and added to increased levels of clinical demand putting immediate procurement pressures on hospitals and building numbers of procedural volume across respiratory and oncology practices.
Advancements in Diagnostic Imaging and Biopsy Guidance Technologies
- The continuous innovation in ultrasound imaging and bronchoscopic navigation has the continuing ability to grow the diagnostic yield and clinical utility for EBUS systems. EBUS systems have a high-resolution image display, AI-based interpretation, and real time tissue mapping tools are widely available, contributing to procedural accuracy and increased diagnostic efficacy to reduce false negativity. As we grow clinician confidence, EBUS can grow even outside the oncology sphere including but not limited to infectious and inflammatory diseases. In addition, continued research and development of smaller and simpler ultrasound processors that have a smaller footprint and easier to more quickly interpret make it is easier to integrate ultrasound in outpatient and community health care, which can accelerate adoption in a variety of healthcare system access points.
Endobronchial Ultrasound Biopsy Market Restraints
High Cost of Equipment and Procedure Implementation
- Though clinical innovations, EBUS systems remain expensive to acquire, maintain, and implement. This has and always will be a barrier to the adoption of EBUS systems, especially for smaller facilities and institutions located within low- and middle-income countries. The costs associated with capital equipment, disposable biopsy needles, and annual servicing are burdening hospitals. This economic burden means that in many circumstances adoption was limited to large tertiary hospitals or academic centres, thus limiting the potential to regulate the market and providing access to patients within broader care settings. There are no efficient procurement avenues or volume-based subsidies that alleviate this burden, making it increasingly difficult for health administrators to acquire EBUS systems and provide advanced diagnostic technologies at scale.
Variability in Reimbursement and Limited Procedure Standardization
- Unpredictable reimbursement structures for procedures across global healthcare markets are limiting fees for procedures. Even though developed countries, specifically, have provided reimbursement for EBUS-TBNA, reimbursement can differ at times of the year, by insurer, and region, which has the potential to limit the ROI for providers. Additionally, a lack of standardized clinical pathways is easily palpable, as is operator variability, which impacts diagnosis. The problem is magnified in lower-volume centres. The differentials created by these types of variables can deter institutions from adopting EBUS systems, particularly in areas lacking thorough lung cancer diagnostics guidelines. To that end, EBUS systems have many well-established clinical benefits, yet the market could be more accelerated without these impediments.
Request Free Customization of this report to help us to meet your business objectives.
Endobronchial Ultrasound Biopsy Market Competitive Landscape
Established companies including Olympus Corporation, Boston Scientific, and FUJIFILM Holdings Corporation continue to make an impact on the global Endobronchial Ultrasound (EBUS) Biopsy Market through innovation and expansion. Olympus continues to exert a competitive advantage based on continuous improvements in their EBUS scopes and imaging systems that offer AI-assisted diagnostics targeted for each region, which provides improved accuracy for bronchoscopy and lung cancer staging. Similarly, Boston Scientific is increasing its competitive position by partnering with MedTech start-ups focusing on AI implementation, by enhancing their existing EBUS tools with next-generation image-guided navigation to improve tissue targeting and accuracy of the biopsy which play a vital role in early cancer diagnosis.
At the same time, FUJIFILM Holdings continues to execute upon its strategy through extensive clinician education and large rollout of global programs by advancing opportunities for clinicians with investment into live training workshops throughout Asia and Europe and planning for a launch in 2024 as part of a robotic navigation-enabled lung cancer diagnostic initiative which demonstrates the wider directional shift of the EBUS industry towards fully integrated, end-to-end, and AI-enabled diagnostic ecosystems. Not only do these leading companies shape product innovation, but rethinking how EBUS technologies are delivered, implemented and scaled within each healthcare environment.
- Founded in 2020, Vektor Medical is the company behind software that overlays anatomical landmarks onto live EBUS diagnostic images to improve accuracy in localizing lesions. In 2023, it was awarded the FDA breakthrough designation and launched pilot implementations at important teaching hospitals around the United States. Vektor uses a cloud-based model that eliminates the complexity normally associated with IT requirements and supports scaling solutions in academic and private clinical settings.
- Established in 2021, NovaScope's mission is to first, build an integrated bronchoscopy kit that includes portable ultrasound systems to serve regional hospitals and mobile diagnostic units. In 2024, NovaScope was successful in obtaining a grant from India's MedTech Innovation Scheme to partner with AIIMS Delhi on pre-clinical trials. By focussing on low-cost, affordable solutions and deploying structures that facilitate mobility, NovaScope highlights the procedural void for the provision of healthcare in rural and underserved regions.
Top Player’s Company Profiles
- Boston Scientific Corporation
- CONMED Corporation
- Olympus Corporation
- Medtronic
- Cook Group
- GE Healthcare
- Siemens Healthcare Private Limited
- Koninklijke Philips N.V.
- Boston Scientific Corporation
- FUJIFILM Holdings Corporation
- ACE Medical Devices Pvt. Ltd.
- Praxis Medical
Recent Developments in Endobronchial Ultrasound Biopsy Market
- In April 2024, Olympus Corporation (Japan) will celebrate 20 years of EBUS by introducing its third-generation BF-UC290F bronchoscope, a new slim-tip bronchoscope that boasts increased angulation (160° upward), and a more narrow 6.6 mm profile, and improves mobility, enabling better accessibility to lymph nodes not previously possible during EBUS-TBNA. The evolution reflects Olympus's consistent momentum in introducing innovative new products to the market, and providing pulmonologists with unencumbered tools of precision, while bolstering its place in high-yield EBUS-guided examinations and TBNA procedures.
- In September 2024, FUJIFILM (Japan) recently deployed the ARIETTA 750 FF ENDO high-end ultrasound processor, recently released for use with EBUS and other endoscopes. The processor highlights advanced market features such as eFocusing and Detective Flow Imaging, wholly enhancing clarity in real-time imaging and evolving diagnostic precision. This commitment reinforces FUJIFILM's intention towards platform level technology, as it continues its strategy toward improving healthcare and clinical outcomes with relatively new technologies and increasing market density in systems utilization for diagnostic imaging.
- In July 2024, a study reported on the initial prototype of a hybrid H-EBUS endoscope, which has a wider field of view and deeper peripheral airway access than prior endoscope iterations. A previous limitation was the endoscope's tip diameter (5.9 mm) and angulation (no greater than 170°). The type of development could replace standard/single purpose bronchoscopes for use in diagnosing peripheral pulmonary lesions. This and several other hybrid avenues illustrate how the health and healthcare support markets are moving toward multi-function all-in-one imaging platforms.
Endobronchial Ultrasound Biopsy Key Market Trends
- Integration of AI in EBUS Imaging and Navigation: The growing use of AI-assisted imaging and diagnostic navigation is a significant trend in the EBUS market. AI algorithms are being utilized more and more to facilitate the identification of lymph nodes, automate the identification of lesions and increase biopsy accuracy and quality. As a result, the amount of variability between operators is decreased and diagnostic accuracy is increased, especially in the diagnosis of early-stage lung cancer. Healthcare organizations using EBUS platforms that integrate AI are realizing shorter procedure times, improved outcomes, as well as improved efficiency. This is clearly an important area of technological and clinical advancement.
- Expansion of Outpatient and Ambulatory EBUS Procedures: As healthcare systems improve efficiencies and reduce hospitalization costs, we see EBUS procedures often moving to ambulatory surgical centers (ASCs) or non-hospital outpatient settings. EBUS is organically decentralizing. Compact, mobile EBUS units and seamless workflows provided by EBUS technology are certainly a factor being considered. This decentralization or ABUS trend is primarily occurring in North America and Europe.... Value-based care systems, plus patients' preference for minimally invasive diagnostics, are all perfectly combining with the demand for EBUS to emerge in more applicable healthcare settings. This is creating an opportunity for greater number of patients to gain access to advanced lung diagnostic testing and relieving some pressure and volume from the tertiary care centres.
Endobronchial Ultrasound Biopsy Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the endobronchial ultrasound biopsy market is driven by the ever-increasing global incidences of lung cancer and the demand in that region for early minimally invasive diagnostics. The biggest restraint to the market is the overall cost of EBUS equipment and procedures, which limits its adoption in a lower-income area. North America leads in this market because it has a robust reimbursement ecosystem for EBUS and historically embraced this technology early on. The hospital segment is the most common end-use segment because of the volume of procedures and accessibility to the equipment. A secondary market driver for this technology is the increase of imaging tools utilizing artificial intelligence, enhancing diagnostic accuracy and reducing operator variability, which is further supporting the global market.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 710.0 million |
| Market size value in 2032 | USD 1092.04 million |
| Growth Rate | 4.9% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Endobronchial Ultrasound Biopsy Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Endobronchial Ultrasound Biopsy Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Endobronchial Ultrasound Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Endobronchial Ultrasound Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Endobronchial Ultrasound Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Endobronchial Ultrasound Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
Want to customize this report?
REQUEST FREE CUSTOMIZATION
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
